YU3501A - Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze - Google Patents

Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze

Info

Publication number
YU3501A
YU3501A YU3501A YU3501A YU3501A YU 3501 A YU3501 A YU 3501A YU 3501 A YU3501 A YU 3501A YU 3501 A YU3501 A YU 3501A YU 3501 A YU3501 A YU 3501A
Authority
YU
Yugoslavia
Prior art keywords
coadministration
acat
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
YU3501A
Other languages
English (en)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU3501A publication Critical patent/YU3501A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Ovaj pronalazak se odnosi na zajedničko ordiniranje inhibitora ACAT i MMP radi umanjivanja aterosklerotičnih oštećenja i makrofaga i ćelijskih komponenata glatkih mišića, čime se zaustavlja širenje već postojećih oštećenja i razvoj novih oštećenja, kao i za prevenciju raskidanja plaka i poboljšanje povlačenja oštećenja kod sisara.[This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal.
YU3501A 1998-07-21 1999-06-18 Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze YU3501A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21

Publications (1)

Publication Number Publication Date
YU3501A true YU3501A (sh) 2005-06-10

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
YU3501A YU3501A (sh) 1998-07-21 1999-06-18 Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze

Country Status (25)

Country Link
EP (1) EP1098662A2 (sh)
JP (1) JP2002521328A (sh)
KR (1) KR20010083134A (sh)
CN (1) CN1310629A (sh)
AP (1) AP2001002035A0 (sh)
AU (1) AU4701799A (sh)
BG (1) BG105162A (sh)
BR (1) BR9912296A (sh)
CA (1) CA2335062A1 (sh)
CZ (1) CZ2001126A3 (sh)
EA (1) EA200100153A1 (sh)
EE (1) EE200100046A (sh)
HR (1) HRP20010055A2 (sh)
HU (1) HUP0102880A3 (sh)
ID (1) ID30030A (sh)
IL (1) IL140982A0 (sh)
IS (1) IS5809A (sh)
NO (1) NO20010291L (sh)
OA (1) OA11584A (sh)
PL (1) PL346011A1 (sh)
SK (1) SK502001A3 (sh)
TR (1) TR200100205T2 (sh)
WO (1) WO2000004892A2 (sh)
YU (1) YU3501A (sh)
ZA (1) ZA200100294B (sh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1210401A (en) * 1999-11-05 2001-06-06 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
WO2002020009A1 (fr) * 2000-09-01 2002-03-14 Sankyo Company, Limited Compositions medicales
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
JP4617449B2 (ja) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
GEP20012511B (en) * 1995-08-04 2001-08-27 Warner Lambert Co Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
EA001561B1 (ru) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
NZ333063A (en) * 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ID30030A (id) 2001-11-01
AU4701799A (en) 2000-02-14
IS5809A (is) 2001-01-12
HUP0102880A3 (en) 2002-11-28
CZ2001126A3 (cs) 2002-01-16
TR200100205T2 (tr) 2001-05-21
NO20010291D0 (no) 2001-01-18
HRP20010055A2 (en) 2002-04-30
WO2000004892A2 (en) 2000-02-03
CN1310629A (zh) 2001-08-29
PL346011A1 (en) 2002-01-14
ZA200100294B (en) 2002-01-10
AP2001002035A0 (en) 2001-03-31
NO20010291L (no) 2001-01-18
KR20010083134A (ko) 2001-08-31
CA2335062A1 (en) 2000-02-03
OA11584A (en) 2004-07-20
EP1098662A2 (en) 2001-05-16
EA200100153A1 (ru) 2001-08-27
BG105162A (en) 2001-12-29
HUP0102880A2 (en) 2002-06-29
EE200100046A (et) 2002-06-17
SK502001A3 (en) 2002-06-04
BR9912296A (pt) 2001-04-17
IL140982A0 (en) 2002-02-10
JP2002521328A (ja) 2002-07-16
WO2000004892A3 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
YU3501A (sh) Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze
AU2713600A (en) Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
PT1011682E (pt) Contraceptivo hormonal
EP1100392A4 (en) METHODS AND DEVICES FOR REDUCING THE MINERAL CONTENT OF VASCULAR CALCIFIED LESIONS
MY127812A (en) New use for budesonide and formoterol
BG105369A (en) Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp
IL128080A0 (en) Thiol sulfonamide metalloprotease inhibitors
AU3103099A (en) Microbubble-based ultrasonic contrast agents for pressure measurements
MXPA02012713A (es) Combinacion de inhibidores de fructosabisfosfatasas y agentes antidiabeticos, util para el tratamiento de la diabetes.
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
MXPA01005165A (es) Aparato de frenado de emergencia de modo doble y metodo para su uso.
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
HK1038198A1 (en) Use of eletriptan in the manufacture of a medicament for the prevention of migraine recurrence.
AU3364899A (en) Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
HUP9801075A3 (en) Fixed-dose association of an angiotensinconverting enzyme inhibitor and of a calcium channel antagonist, method for preparation and use thereof in the treatment of cardiovascular illnesses
NO20012569D0 (no) Anvendelse av aryl-substituerte syklobutylaminer for behandling av urininkontinens
WO1999002565A3 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
IT1302813B1 (it) Dispositivo per la riduzione diretta di ossidi di ferroe relativo procedimento
AU4144099A (en) Use of an agent for the prevention of gum disease
GB0029207D0 (en) Brake shoe and internal shoe drum brake
MXPA02011810A (es) Utilizacion del riluzol o sus sales para la prevencion y el tratamiento de la adrenoleucodistrofia.
TW374520U (en) Increasing and deducting structure for the metal guide foot of the computer line terminals
SI1100499T1 (en) Use of eletriptan for the prevention of migraine recurrence
ES1040950Y (es) Conjunto integrado para la higiene intima femenina.